Supplementary Figure 2: Effects of the NAMPT inhibitor FK866 and KYN supplementation.
From: Macrophage de novo NAD+ synthesis specifies immune function in aging and inflammation

a, Diagram of the site of action of 1MT and phthalic acid (PTH), selective inhibitors of IDO1 and QPRT, respectively. b, Representative flow cytometry plot from three independent experiments of cells treated for 20 h with either vehicle, 1MT (200 μM), or pthalic acid (PTH, 500 μM) stained with propidium iodide (n = 25,000–30,000 cells per group). c, Gating strategy for huMDMs. d–h, HuMDMs were treated with the IDO1 inhibitor 1MT (200 μM, 20 h). d, LC/MS measurement of NAD+; n = 3 biologically independent samples per group, shown as mean ± S.E.; *P = 0.0233 by Student’s two-tailed t test. e, Representative trace from three independent experiments for effect of 1MT on OCR, n = 10 biologically independent samples/group, shown mean ± S.E. f, Effects of 1MT on basal respiration, maximal respiration, and spare respiratory capacity; n = 3 biologically independent samples per group, shown as mean ± S.E.; ***P = 0.0004 for basal respiration, ***P = 0.0006 for maximal respiration, and **P = 0.0087 for spare respiratory capacity by Student’s two-tailed t test. g, Effect of 1MT on ECAR; n = 3 biologically independent samples/group, mean ± S.E.; *P = 0.0411 by Student’s two-tailed t test. h, Peritoneal macrophages from WT and Ido1–/– mice were supplemented with either vehicle or 25 μM KYN for 20 h and assayed for spare respiratory capacity and maximal respiration; n = 6 biologically independent samples per WT group and n = 9 biologically independent samples per Ido1–/– group, represented as mean ± S.E.; two-way ANOVA, effect of genotype P < 0.0001 for both, effect of KYN P < 0.05 and P < 0.0001 for spare respiratory capacity and max respiration, respectively; Tukey post hoc ***P = 0.0001, *P = 0.0200, and ****P < 0.0001. i, Permeabilized macrophages from WT and Ido1–/– mice were stimulated with complex-specific substrates, including pyruvate + malate for assessing complex I, succinate + rotenone for complex II, duroquinol for complex III, and TMPD + ascorbate for complex IV. Data are represented as mean ± S.E.; n = 8 biologically independent samples per group; ****P < 0.0001 by Student’s two-tailed t test.